Pfizer drug prices – The Milli Chronicle

Wednesday, October 1, 2025

Latest:

India’s Central Bank Maintains Rates, Signals Support for Growth and Economic Resilience
India’s Manufacturing Sector Shows Resilience as Business Optimism Hits Seven-Month High
Indian Stock Markets Rally as Central Bank Lending Boost Sparks Gains
India Set for $8 Billion IPO Wave as Market Shows Strong Investor Appetite
Assam Reassesses Clean Energy Policy, Opportunities Remain for Renewable Investments

Featured News World

NewsDesk Milli Chronicle October 1, 2025October 1, 2025 healthcare policy news, international drug pricing standards, Medicaid drug price cuts, Pfizer CEO Albert Bourla, Pfizer drug prices, Pfizer global pricing, Pfizer lowers drug prices, Pfizer pharmaceutical news, Pfizer shares surge, Pfizer White House agreement, pharmaceutical industry reforms, prescription drug price reform, Trump administration healthcare deal, Trump administration pharma deal, Trump healthcare policy, TrumpRx platform, U.S. drug pricing reform, U.S. healthcare affordability, U.S. prescription drug costs, White House healthcare initiative

Pfizer Strikes Landmark Deal With Trump Administration to Lower Drug Prices

In a move hailed as a turning point for U.S. healthcare, Pfizer agrees to align drug prices with global standards